At many doctors’ offices and hospitals, a routine part of doing business these days is estimating patients’ out-of-pocket payments and trying to collect it up front

Quick Read

In this town, carved into the Appalachian mountains, in a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach. Over the past year, only 3 percent of the state’s Medicaid beneficiaries with the disease received treatment

Quick Read

The Affordable Care Act transformed the medical system, expanding coverage to millions, injecting billions in tax revenue, changing insurance rules and launching ambitious experiments in quality and efficiency

Quick Read

Republicans have been vowing for six years now to repeal the Affordable Care Act. They have voted to do so dozens of times, despite knowing any measures would be vetoed by President Obama

Quick Read

“Most medical devices are designed for places like here, not low-income clinics,” Donaldson said in reference to clinics in wealthy nations that can more easily afford and maintain the prosthetics. D-Rev created more affordable prosthetic limbs to help amputees worldwide who don’t have access to the medical devices

Quick Read

Dealmakers have always flipped companies. Lately, they’ve been flipping something else: aging pharmaceuticals

Quick Read

Martin Shkreli. Valeant Pharmaceuticals. Mylan. These names have become big news, but just a year ago, most Americans devoted little time and attention to the question of pharmaceutical pricing. Now, a Kaiser Health Tracking Poll released Oct. 27 suggests many people care more about the increasing prices of drugs than they do about any other aspect of health care reform

Quick Read

Another pharmaceutical company is coming under fire for boosting the price of one of its drugs. Two lawmakers are demanding to know the justification for a more than $80,000 price hike for a year’s supply of a drug that treats leukemia patients

Quick Read